These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
155 related articles for article (PubMed ID: 1523100)
1. Impaired fibrinolytic response to DDAVP in patients with von Willebrand's disease. Sultan Y; Loyer F; Venot A Nouv Rev Fr Hematol (1978); 1992; 34(1):55-60. PubMed ID: 1523100 [TBL] [Abstract][Full Text] [Related]
2. Secretory response of the vessel wall to DDAVP and venous occlusion in von Willebrand's disease. Bykowska K; Letowska M; Sabliński J; Binder BR; Kopeć M; Lopaciuk S Acta Haematol Pol; 1994; 25(3):261-8. PubMed ID: 7992599 [TBL] [Abstract][Full Text] [Related]
3. Study of endothelial t-PA and vWf in normal subjects and in von Willebrand's disease. Wieczorek I; Ludlam CA; MacGregor IR Blood Coagul Fibrinolysis; 1994 Jun; 5(3):329-34. PubMed ID: 8075304 [TBL] [Abstract][Full Text] [Related]
4. Blood fibrinolysis and the response to desmopressin in glomerulonephritis. Brommer EJ; Van den Wall Bake AW; Dooijewaard G; van Loon BJ; Emeis JJ; Weening JJ Thromb Haemost; 1994 Jan; 71(1):19-25. PubMed ID: 8165642 [TBL] [Abstract][Full Text] [Related]
5. Fibrinolytic and haemostatic responses to desamino-D-arginine vasopressin (DDAVP) administered by intravenous and subcutaneous routes in healthy subjects. MacGregor IR; Roberts EM; Prowse CV; Broomhead AF; Ozolins M; Litka P Thromb Haemost; 1988 Feb; 59(1):34-9. PubMed ID: 3129807 [TBL] [Abstract][Full Text] [Related]
7. Response of von Willebrand factor parameters to desmopressin in patients with type 1 and type 2 congenital von Willebrand disease: diagnostic and therapeutic implications. Michiels JJ; van de Velde A; van Vliet HH; van der Planken M; Schroyens W; Berneman Z Semin Thromb Hemost; 2002 Apr; 28(2):111-32. PubMed ID: 11992235 [TBL] [Abstract][Full Text] [Related]
8. Impaired release of tissue plasminogen activator (t-PA) following DDAVP infusion in von Willebrand's disease with low platelet von Willebrand factor content. Casonato A; Sartori MT; Pontara E; Zucchetto A; Dannhäuser D; Patrassi G; Girolami A Blood Coagul Fibrinolysis; 1992 Apr; 3(2):149-53. PubMed ID: 1606286 [TBL] [Abstract][Full Text] [Related]
9. The effect of desamino-D-arginine vasopressin (DDAVP) and naloxone infusions on factor VIII and possible endothelial cell (EC) related activities. Moffat EH; Giddings JC; Bloom AL Br J Haematol; 1984 Aug; 57(4):651-62. PubMed ID: 6430337 [TBL] [Abstract][Full Text] [Related]
11. Evaluation of desmopressin effects on haemostasis in children with congenital bleeding disorders. Hanebutt FL; Rolf N; Loesel A; Kuhlisch E; Siegert G; Knoefler R Haemophilia; 2008 May; 14(3):524-30. PubMed ID: 18284449 [TBL] [Abstract][Full Text] [Related]
12. Factor VII and fibrinolytic response to deamino-8-D-argenine vasopressin in normal subjects and dissociate response in some patients with haemophilia and von Willebrand's disease. Ludlam CA; Peake IR; Allen N; Davies BL; Furlong RA; Bloom AL Br J Haematol; 1980 Jul; 45(3):499-511. PubMed ID: 6775673 [TBL] [Abstract][Full Text] [Related]
13. Different tissue plasminogen activator release in the arm and leg during venous occlusion is equalized after DDAVP infusion. Keber D; Stegnar M; Kluft C Thromb Haemost; 1990 Feb; 63(1):72-5. PubMed ID: 2111049 [TBL] [Abstract][Full Text] [Related]
14. A new variant of von Willebrand's disease (type I Padua): doublet-organized plasma von Willebrand factor oligomers in the presence of all size multimers. Casonato A; Pontara E; Dannhäuser D; Bertomoro A; Sartori MT; Girolami A Haematologia (Budap); 1994; 26(2):97-109. PubMed ID: 7890268 [TBL] [Abstract][Full Text] [Related]
15. Laboratory diagnosis of von Willebrand disease type 1/2E (2A subtype IIE), type 1 Vicenza and mild type 1 caused by mutations in the D3, D4, B1-B3 and C1-C2 domains of the von Willebrand factor gene. Role of von Willebrand factor multimers and the von Willebrand factor propeptide/antigen ratio. Gadisseur A; Berneman Z; Schroyens W; Michiels JJ Acta Haematol; 2009; 121(2-3):128-38. PubMed ID: 19506359 [TBL] [Abstract][Full Text] [Related]
16. Intravenous DDAVP and factor VIII-von Willebrand factor concentrate for the treatment and prophylaxis of bleedings in patients With von Willebrand disease type 1, 2 and 3. Michiels JJ; van Vliet HH; Berneman Z; Gadisseur A; van der Planken M; Schroyens W; van der Velden A; Budde U Clin Appl Thromb Hemost; 2007 Jan; 13(1):14-34. PubMed ID: 17164493 [TBL] [Abstract][Full Text] [Related]
18. The fibrinolytic system in the hemolytic uremic syndrome: in vivo and in vitro studies. van de Kar NC; van Hinsbergh VW; Brommer EJ; Monnens LA Pediatr Res; 1994 Aug; 36(2):257-64. PubMed ID: 7970942 [TBL] [Abstract][Full Text] [Related]
19. Behaviour of tissue plasminogen activator, plasminogen activator inhibitor 1 and their complex in various disease states. Niwano H; Takahashi H; Tatewaki W; Wada K; Seki Y; Shibata A Blood Coagul Fibrinolysis; 1992 Aug; 3(4):389-93. PubMed ID: 1420814 [TBL] [Abstract][Full Text] [Related]
20. Acquired von Willebrand's syndrome associated with decrease of plasminogen activator and its inhibitor during hypothyroidism. Levesque H; Borg JY; Cailleux N; Vasse M; Daliphard S; Gancel A; Monconduit M; Courtois H Eur J Med; 1993 May; 2(5):287-8. PubMed ID: 8252160 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]